Watch for Insurance Flags or Rejects for Specialty Meds

You'll hear more about specialty meds...evolocumab (Repatha), imatinib (Gleevec, etc), ledipasvir/sofosbuvir (Harvoni), etc.

Specialty meds account for about half of new drugs approved in 2015...and these meds will make up over half of drug spending by 2017.

What makes specialty meds "special"? They're generally high-cost and "high-touch"...such as requiring specific testing before starting the med, a detailed monitoring plan, or unique storage.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals